MIRA
INFORM REPORT
|
Report Date : |
09.10.2007 |
IDENTIFICATION DETAILS
|
Name : |
ARKRAY GLOBAL
BUSINESS INC |
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.10.2006 |
|
|
|
|
Date of Incorporation : |
Jul 2001 |
|
|
|
|
Legal Form : |
Limited Company (Kabushiki Kaisha) |
|
|
|
|
Line of Business : |
Manufacturingg, export of diabetes-related
clinical equipment & supplies |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
Yen 1006.2 millions |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
-- |
name
ARKRAY GLOBAL
BUSINESS INC
REGD NAME
Arkray Global
Business KK (Overseas trading division of Arkray Inc)
MAIN OFFICE
Tel : 050-5527-9306
Fax : 075-662-8973
URL : http://www.arkray.co.jp
E-Mail address: info@arkray.co.jp
*.. The given address is its Laboratory at: 57 Nishi-Aketacho
Higashi Kujo Minamiku
ACTIVITIES
Mfg, export of
diabetes-related clinical equipment & supplies
BRANCHES
Nationwide (Tot
23)
OVERSEAS
Europe,
FACTORY(IES)
Shiga (2)
(Overseas):
OFFICERS
SHIGERU DOI, PRES Sunako Doi, ch
Masayoshi
Nonogaki, dir Shigeki
Yamada, dir
Yen Amount: In million Yen, unless otherwise stated
SUMMARY
FINANCES FAIR A/SALES Yen 55,530 M*
PAYMENTS REGULAR CAPITAL Yen 793 M*
TREND STEADY WORTH Yen
3,199 M*
STARTED 1963 EMPLOYES 326
*.. All figures are of the parent, Arkray Inc, as the subject does not release financials as they are consolidated by the parent.
COMMENT
EXPORTER OF DIABETES-RELATED CLINICAL EQUIPMENT, WHOLLY OWNED
BY ARKRAY INC. FINANCIAL SITUATION
CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.
MAX CREDIT LIMIT: YEN 1,006.2 MILLION, 30 DAYS NORMAL TERMS.
HIGHLIGHTS
The subject company was established on the overseas trading
division separated from Arkray Inc, mfg of diabetes-related clinical
instruments, at the caption address.
This is an overseas trading division of the parent with management and
staff members fully integrated with the parent, Arkray Inc. Specializes in
exporting the goods of the parent to over 80 countries worldwide. Sales offices are in Europe,
(Affiliates):
Domestic: Arkray Marketing Inc (Domestic marketing division);
Arkray Global Business Inc (International
marketing division);
Arkray Infinity Inc, Arkray
Factory Inc (--Mfg divisions);
Arkray Digital Laboratory Inc (PC software development);
Arkray Optron Inc (Mfg of optical goods)
Overseas: Arkray
Global Inc
Arkray Marketing Shanghai Inc,
Arkray Factory USA Inc; Arkray Factory Shanghai Inc (--Mfg)
FINANCIAL
INFORMATION
Financials are not disclosed as they are consolidated by the parent, Arkray Inc, which financials are only partially disclosed.
The sales volume for Oct/2006 fiscal term amounted to Yen
55,530 million, a 4% up from Yen 53,300 million in the previous term. Exports increased particularly to
For the current term ending Oct 2007 the net profit is projected at Yen 265 million, on a 3.5% rise in turnover, to Yen 57,500 million. Weaker Yen will help uplift sales amount in Yen terms.
The financial situation is considered FAIR and good for ORDINARY business engagements. Max credit limit of the parent, Arkray Inc, is estimated at Yen 1,006.2 million, on 30 days normal terms.
REGISTRATION
Date Registered: Jul 2001
Legal Status: Limited Company (Kabushiki
Kaisha)
Authorized: 800 shares
Issued: 200 shares
Sum: Yen 10 million
Major shareholders
(%): Arkray Inc*(100)
*.. Mfr of diabetes-related clinical testing equipment, at the caption address, founded 1963, capital Yen 793 million, employees 223, pres Shigeru Doi, concurrently;
Financials as attached.
Nothing
detrimental is known as to the commercial morality of executives.
OPERATION
Activities: Exports diabetes-related clinical equipment & supplies, reagents, functional foods as overseas trading division of Arkray Inc to over 80 countries worldwide (--100%).
(Handling items):
Automatic Glycohemoglobin Analyzer, Fully Automated Urine
Analyzer, Versatile Urine Analysis System, Compact Urine Analyzer, Urine test
strips, Dry Clinical Chemistry Analyzer, Automated analyzer for clinical
chemistry, Electrolyte Analyzer with Ion-Selective Electrodes, Blood Ammonia
Meter, Blood glucose test meter, Lancet device for blood collection, Osmotic Pressure,
Simplified Blood Lactate Test Meter,
(Principal overseas clients):
Bayer Corporation (USA); A Menarini Diagnostic (Italy); Tamro Corporation (Finland); Axon Lab AG (Switz); Heska Corporation (USA); IRIS (USA)
Clients: [Hospitals, laboratories, medical institutions]
Exports to
No. of accounts:
Unavailable
Domestic areas of
activities: Nationwide
Suppliers: [Mfr]
Supplied wholly from the parent, Arkray Inc.
Payment record:
Regular
Location: Business area in
Bank References
Bank of
MUFG (Kyoto-Chuo)
Relations:
Satisfactory
FINANCES
(In Million Yen)
Consolidated
Financials of the parent, Arkray Inc.
|
Terms Ending: |
|
31/10/2007 |
31/10/2006 |
31/10/2005 |
31/10/2004 |
|
|
Annual
Sales |
|
57,500 |
55,530 |
53,300 |
51,147 |
|
|
Recur.
Profit |
(*) |
|
|
420 |
348 |
|
|
Net
Profit |
|
265 |
260 |
252 |
208 |
|
|
Total
Assets |
|
|
N/A |
N/A |
N/A |
|
|
Net
Worth |
|
|
3,199 |
3,017 |
2,841 |
|
|
Capital,
Paid-Up |
|
|
793 |
793 |
7,933 |
|
|
Div.P.Share(¥) |
|
|
|
|
|
|
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
||
|
S.Growth Rate |
3.55 |
4.18 |
4.21 |
-5.67 |
||
|
Current Ratio |
|
|
.. |
.. |
.. |
|
|
N.Worth Ratio |
|
.. |
.. |
.. |
||
|
N.Profit/Sales |
0.46 |
0.47 |
0.47 |
0.41 |
||
Note: Financials
are only partially disclosed.
Forecast (or estimated)
for the 31/10/2007 fiscal term.
(*) Pretax profits
disclosed from the Taxation Office.
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)